nach oben

Diabetologia

Erschienen in:

09.01.2019 | Article

Carvedilol prevents counterregulatory failure and impaired hypoglycaemia awareness in non-diabetic recurrently hypoglycaemic rats

verfasst von: Rawad Farhat, Gong Su, Anne-Sophie Sejling, Nicholas Knight, Simon J. Fisher, Owen Chan

Erschienen in: Diabetologia | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

This study evaluates whether the non-selective β-blocker, carvedilol, can be used to prevent counterregulatory failure and the development of impaired awareness of hypoglycaemia (IAH) in recurrently hypoglycaemic rats.

Methods

Sprague Dawley rats were implanted with vascular catheters and intracranial guide cannulas targeting the ventromedial hypothalamus (VMH). These animals underwent either three bouts of insulin-induced hypoglycaemia or received three saline injections (control group) over 3 days. A subgroup of recurrently hypoglycaemic animals was treated with carvedilol. The next day, the animals underwent a hypoglycaemic clamp with microdialysis without carvedilol treatment to evaluate changes in central lactate and hormone levels. To assess whether carvedilol prevented IAH, we treated rats that had received repeated 2-deoxyglucose (2DG) injections to impair their awareness of hypoglycaemia with carvedilol and measured food intake in response to insulin-induced hypoglycaemia as a surrogate marker for hypoglycaemia awareness.

Results

Compared with the control group, recurrently hypoglycaemic rats had a ~1.7-fold increase in VMH lactate and this was associated with a 75% reduction in the sympathoadrenal response to hypoglycaemia. Treatment with carvedilol restored VMH lactate levels and improved the adrenaline (epinephrine) responses. In 2DG-treated rats compared with control animals receiving saline, food intake was reduced in response to hypoglycaemia and increased with carvedilol treatment.

Conclusions/interpretation

We conclude that carvedilol may be a useful therapy to prevent counterregulatory failure and improve IAH.

Nur mit Berechtigung zugänglich

Cryer PE (2008) The barrier of hypoglycemia in diabetes. Diabetes 57(12):3169–3176. https://doi.org/10.2337/db08-1084 CrossRefPubMedPubMedCentral

Cryer PE (2008) Hypoglycemia: still the limiting factor in the glycemic management of diabetes. Endocr Pract 14(6):750–756. https://doi.org/10.4158/EP.14.6.750 CrossRefPubMed

Cryer PE (2001) Hypoglycemia-associated autonomic failure in diabetes. Am J Physiol Endocrinol Metab 281(6):E1115–E1121. https://doi.org/10.1152/ajpendo.2001.281.6.E1115 CrossRefPubMed

Cryer PE (2004) Diverse causes of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med 350(22):2272–2279. https://doi.org/10.1056/NEJMra031354 CrossRefPubMed

Cryer PE (2005) Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes 54(12):3592–3601. https://doi.org/10.2337/diabetes.54.12.3592 CrossRefPubMed

Chan O, Sherwin R (2013) Influence of VMH fuel sensing on hypoglycemic responses. Trends Endocrinol Metab 24(12):616–624. https://doi.org/10.1016/j.tem.2013.08.005 CrossRefPubMedPubMedCentral

Chenal J, Pellerin L (2007) Noradrenaline enhances the expression of the neuronal monocarboxylate transporter MCT2 by translational activation via stimulation of PI3K/Akt and the mTOR/S6K pathway. J Neurochem 102(2):389–397. https://doi.org/10.1111/j.1471-4159.2007.04495.x CrossRefPubMed

Pralong E, Magistretti PJ (1994) Noradrenaline reduces synaptic responses in normal and tottering mouse entorhinal cortex via alpha 2 receptors. Neurosci Lett 179(1-2):145–148. https://doi.org/10.1016/0304-3940(94)90955-5 CrossRefPubMed

Pierre K, Debernardi R, Magistretti PJ, Pellerin L (2003) Noradrenaline enhances monocarboxylate transporter 2 expression in cultured mouse cortical neurons via a translational regulation. J Neurochem 86(6):1468–1476. https://doi.org/10.1046/j.1471-4159.2003.01964.x CrossRefPubMed

10.

Barnes MB, Lawson MA, Beverly JL (2011) Rate of fall in blood glucose and recurrent hypoglycemia affect glucose dynamics and noradrenergic activation in the ventromedial hypothalamus. Am J Physiol Regul Integr Comp Physiol 301(6):R1815–R1820. https://doi.org/10.1152/ajpregu.00171.2011 CrossRefPubMedPubMedCentral

11.

Szepietowska B, Zhu W, Chan O, Horblitt A, Dziura J, Sherwin RS (2011) Modulation of beta-adrenergic receptors in the ventromedial hypothalamus influences counterregulatory responses to hypoglycemia. Diabetes 60(12):3154–3158. https://doi.org/10.2337/db11-0432 CrossRefPubMedPubMedCentral

12.

Szepietowska B, Zhu W, Sherwin RS (2013) beta2-Adrenergic receptor agonist administration promotes counter-regulatory responses and recovery from hypoglycaemia in rats. Diabetologia 56(11):2517–2523. https://doi.org/10.1007/s00125-013-3009-7 CrossRefPubMed

13.

de Vries MG, Lawson MA, Beverly JL (2004) Dissociation of hypothalamic noradrenergic activity and sympathoadrenal responses to recurrent hypoglycemia. Am J Physiol Regul Integr Comp Physiol 286(5):R910–R915. https://doi.org/10.1152/ajpregu.00254.2002 CrossRefPubMed

14.

Figlewicz DP, Van Dijk G, Wilkinson CW, Gronbeck P, Higgins M, Zavosh A (2002) Effects of repetitive hypoglycemia on neuroendocrine response and brain tyrosine hydroxylase activity in the rat. Stress 5(3):217–226. https://doi.org/10.1080/1025389021000010558 CrossRefPubMed

15.

Ramanathan R, Cryer PE (2011) Adrenergic mediation of hypoglycemia-associated autonomic failure. Diabetes 60(2):602–606. https://doi.org/10.2337/db10-1374 CrossRefPubMedPubMedCentral

16.

Morsy MA, Ibrahim SA, Amin EF, Kamel MY, Abdelwahab SA, Hassan MK (2014) Carvedilol ameliorates early diabetic nephropathy in streptozotocin-induced diabetic rats. Biomed Res Int 2014:105214CrossRefPubMedPubMedCentral

17.

Sun YL, Hu SJ, Wang LH, Hu Y, Zhou JY (2005) Comparison of low and high doses of carvedilol on restoration of cardiac function and calcium-handling proteins in rat failing heart. Clin Exp Pharmacol Physiol 32(7):553–560. https://doi.org/10.1111/j.1440-1681.2005.04230.x CrossRefPubMed

18.

Ohta Y, Watanabe K, Nakazawa M et al (2000) Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart. J Cardiovasc Pharmacol 36(Suppl 2):S19–S23. https://doi.org/10.1097/00005344-200000006-00006 CrossRefPubMed

19.

Watanabe K, Ohta Y, Nakazawa M et al (2000) Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy. Br J Pharmacol 130(7):1489–1495. https://doi.org/10.1038/sj.bjp.0703450 CrossRefPubMedPubMedCentral

20.

Chan O, Zhu W, Ding Y, McCrimmon RJ, Sherwin RS (2006) Blockade of GABAA receptors in the ventromedial hypothalamus further stimulates glucagon and sympathoadrenal but not the hypothalamo-pituitary-adrenal response to hypoglycemia. Diabetes 55(4):1080–1087. https://doi.org/10.2337/diabetes.55.04.06.db05-0958 CrossRefPubMed

21.

Chan O, Lawson M, Zhu W, Beverly JL, Sherwin RS (2007) ATP-sensitive K(+) channels regulate the release of GABA in the ventromedial hypothalamus during hypoglycemia. Diabetes 56(4):1120–1126. https://doi.org/10.2337/db06-1102 CrossRefPubMed

22.

Osundiji MA, Hurst P, Moore SP et al (2011) Recurrent hypoglycemia increases hypothalamic glucose phosphorylation activity in rats. Metabolism 60(4):550–556. https://doi.org/10.1016/j.metabol.2010.05.009 CrossRefPubMed

23.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25(4):402–408. https://doi.org/10.1006/meth.2001.1262 CrossRefPubMed

24.

Geddes J, Schopman JE, Zammitt NN, Frier BM (2008) Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes. Diabet Med 25(4):501–504. https://doi.org/10.1111/j.1464-5491.2008.02413.x CrossRefPubMed

25.

Geddes J, Wright RJ, Zammitt NN, Deary IJ, Frier BM (2007) An evaluation of methods of assessing impaired awareness of hypoglycemia in type 1 diabetes. Diabetes Care 30(7):1868–1870. https://doi.org/10.2337/dc06-2556 CrossRefPubMed

26.

Sprague JE, Arbelaez AM (2011) Glucose counterregulatory responses to hypoglycemia. Pediatr Endocrinol Rev 9: 463–473; quiz 474–465

27.

Sanders NM, Figlewicz DP, Taborsky GJ Jr, Wilkinson CW, Daumen W, Levin BE (2006) Feeding and neuroendocrine responses after recurrent insulin-induced hypoglycemia. Physiol Behav 87(4):700–706. https://doi.org/10.1016/j.physbeh.2006.01.007 CrossRefPubMed

28.

Sanders NM, Ritter S (2000) Repeated 2-deoxy-D-glucose-induced glucoprivation attenuates Fos expression and glucoregulatory responses during subsequent glucoprivation. Diabetes 49(11):1865–1874. https://doi.org/10.2337/diabetes.49.11.1865 CrossRefPubMed

29.

Sanders NM, Taborsky GJ Jr, Wilkinson CW, Daumen W, Figlewicz DP (2007) Antecedent hindbrain glucoprivation does not impair the counterregulatory response to hypoglycemia. Diabetes 56(1):217–223. https://doi.org/10.2337/db06-1025 CrossRefPubMed

30.

de Vries MG, Lawson MA, Beverly JL (2005) Hypoglycemia-induced noradrenergic activation in the VMH is a result of decreased ambient glucose. Am J Physiol Regul Integr Comp Physiol 289(4):R977–R981. https://doi.org/10.1152/ajpregu.00403.2005 CrossRefPubMed

31.

Bart J, Dijkers EC, Wegman TD et al (2005) New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kinetics. Br J Pharmacol 145(8):1045–1051. https://doi.org/10.1038/sj.bjp.0706283 CrossRefPubMedPubMedCentral

32.

De Feyter HM, Mason GF, Shulman GI, Rothman DL, Petersen KF (2013) Increased brain lactate concentrations without increased lactate oxidation during hypoglycemia in type 1 diabetic individuals. Diabetes 62(9):3075–3080. https://doi.org/10.2337/db13-0313 CrossRefPubMedPubMedCentral

33.

Herzog RI, Jiang L, Herman P et al (2013) Lactate preserves neuronal metabolism and function following antecedent recurrent hypoglycemia. J Clin Invest 123(5):1988–1998. https://doi.org/10.1172/JCI65105 CrossRefPubMedPubMedCentral

34.

Chan O, Paranjape SA, Horblitt A, Zhu W, Sherwin RS (2013) Lactate-induced release of GABA in the ventromedial hypothalamus contributes to counterregulatory failure in recurrent hypoglycemia and diabetes. Diabetes 62(12):4239–4246. https://doi.org/10.2337/db13-0770 CrossRefPubMedPubMedCentral

35.

Wiegers EC, Rooijackers HM, Tack CJ, Heerschap A, de Galan BE, van der Graaf M (2016) Brain lactate concentration falls in response to hypoglycemia in patients with type 1 diabetes and impaired awareness of hypoglycemia. Diabetes 65(6):1601–1605. https://doi.org/10.2337/db16-0068 CrossRefPubMed

36.

Wiegers EC, Rooijackers HM, Tack CJ et al (2017) Effect of exercise-induced lactate elevation on brain lactate levels during hypoglycemia in patients with type 1 diabetes and impaired awareness of hypoglycemia. Diabetes 66(12):3105–3110. https://doi.org/10.2337/db17-0794 CrossRefPubMed

37.

Wiegers EC, Rooijackers HM, Tack CJ, et al (2018) Effect of lactate administration on brain lactate levels during hypoglycemia in patients with type 1 diabetes. J Cereb Blood Flow Metab 271678X18775884

38.

Mason GF, Petersen KF, Lebon V, Rothman DL, Shulman GI (2006) Increased brain monocarboxylic Acid transport and utilization in type 1 diabetes. Diabetes 55(4):929–934. https://doi.org/10.2337/diabetes.55.04.06.db05-1325 CrossRefPubMed

39.

Catus SL, Gibbs ME, Sato M, Summers RJ, Hutchinson DS (2011) Role of beta-adrenoceptors in glucose uptake in astrocytes using beta-adrenoceptor knockout mice. Br J Pharmacol 162(8):1700–1715. https://doi.org/10.1111/j.1476-5381.2010.01153.x CrossRefPubMedPubMedCentral

40.

Subbarao KV, Hertz L (1990) Noradrenaline induced stimulation of oxidative metabolism in astrocytes but not in neurons in primary cultures. Brain Res 527(2):346–349. https://doi.org/10.1016/0006-8993(90)91157-C CrossRefPubMed

41.

Pellerin L, Magistretti PJ (1994) Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci U S A 91(22):10625–10629. https://doi.org/10.1073/pnas.91.22.10625 CrossRefPubMedPubMedCentral

42.

Fray AE, Forsyth RJ, Boutelle MG, Fillenz M (1996) The mechanisms controlling physiologically stimulated changes in rat brain glucose and lactate: a microdialysis study. J Physiol 496(Pt 1):49–57. https://doi.org/10.1113/jphysiol.1996.sp021664 CrossRefPubMedPubMedCentral

43.

Gibbs ME, Hutchinson DS, Summers RJ (2008) Role of beta-adrenoceptors in memory consolidation: beta3-adrenoceptors act on glucose uptake and beta2-adrenoceptors on glycogenolysis. Neuropsychopharmacology 33(10):2384–2397. https://doi.org/10.1038/sj.npp.1301629 CrossRefPubMed

44.

Walls AB, Heimburger CM, Bouman SD, Schousboe A, Waagepetersen HS (2009) Robust glycogen shunt activity in astrocytes: Effects of glutamatergic and adrenergic agents. Neuroscience 158(1):284–292. https://doi.org/10.1016/j.neuroscience.2008.09.058 CrossRefPubMed

45.

Obel LF, Andersen KM, Bak LK, Schousboe A, Waagepetersen HS (2012) Effects of adrenergic agents on intracellular Ca2+ homeostasis and metabolism of glucose in astrocytes with an emphasis on pyruvate carboxylation, oxidative decarboxylation and recycling: implications for glutamate neurotransmission and excitotoxicity. Neurotox Res 21(4):405–417. https://doi.org/10.1007/s12640-011-9296-1 CrossRefPubMed

46.

Pellerin L, Stolz M, Sorg O, Martin JL, Deschepper CF, Magistretti PJ (1997) Regulation of energy metabolism by neurotransmitters in astrocytes in primary culture and in an immortalized cell line. Glia 21(1):74–83. https://doi.org/10.1002/(SICI)1098-1136(199709)21:1<74::AID-GLIA8>3.0.CO;2-1 CrossRefPubMed

47.

Lee JG, Choi IS, Park EJ et al (2007) beta(2)-Adrenoceptor-mediated facilitation of glutamatergic transmission in rat ventromedial hypothalamic neurons. Neuroscience 144(4):1255–1265. https://doi.org/10.1016/j.neuroscience.2006.10.049 CrossRefPubMed

48.

Moreira TJ, Pierre K, Maekawa F et al (2009) Enhanced cerebral expression of MCT1 and MCT2 in a rat ischemia model occurs in activated microglial cells. J Cereb Blood Flow Metab 29(7):1273–1283. https://doi.org/10.1038/jcbfm.2009.50 CrossRefPubMed

49.

Hirsch IB, Boyle PJ, Craft S, Cryer PE (1991) Higher glycemic thresholds for symptoms during beta-adrenergic blockade in IDDM. Diabetes 40(9):1177–1186. https://doi.org/10.2337/diab.40.9.1177 CrossRefPubMed

50.

McGill JB, Bakris GL, Fonseca V et al (2007) beta-blocker use and diabetes symptom score: results from the GEMINI study. Diabetes Obes Metab 9(3):408–417. https://doi.org/10.1111/j.1463-1326.2006.00693.x CrossRefPubMed

51.

Poterucha JT, Bos JM, Cannon BC, Ackerman MJ (2015) Frequency and severity of hypoglycemia in children with beta-blocker-treated long QT syndrome. Heart Rhythm 12(8):1815–1819. https://doi.org/10.1016/j.hrthm.2015.04.034 CrossRefPubMed

52.

Barnett AH, Leslie D, Watkins PJ (1980) Can insulin-treated diabetics be given beta-adrenergic blocking drugs? Br Med J 280(6219):976–978. https://doi.org/10.1136/bmj.280.6219.976 CrossRefPubMedPubMedCentral

53.

Kerr D, MacDonald IA, Heller SR, Tattersall RB (1990) Beta-adrenoceptor blockade and hypoglycaemia. A randomised, double-blind, placebo controlled comparison of metoprolol CR, atenolol and propranolol LA in normal subjects. Br J Clin Pharmacol 29(6):685–693. https://doi.org/10.1111/j.1365-2125.1990.tb03689.x CrossRefPubMedPubMedCentral

54.

Cameron OG (1989) Beta-adrenergic blockade does not prevent hypoglycemia awareness in non-diabetic humans. Psychosom Med 51(2):165–172. https://doi.org/10.1097/00006842-198903000-00006 CrossRefPubMed

55.

Giugliano D, Acampora R, Marfella R et al (1997) Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 126(12):955–959. https://doi.org/10.7326/0003-4819-126-12-199706150-00004 CrossRefPubMed

56.

Park MJ, Guest CB, Barnes MB et al (2008) Blocking of beta-2 adrenergic receptors hastens recovery from hypoglycemia-associated social withdrawal. Psychoneuroendocrinology 33(10):1411–1418. https://doi.org/10.1016/j.psyneuen.2008.08.005 CrossRefPubMedPubMedCentral

Titel: Carvedilol prevents counterregulatory failure and impaired hypoglycaemia awareness in non-diabetic recurrently hypoglycaemic rats
verfasst von: Rawad Farhat
Gong Su
Anne-Sophie Sejling
Nicholas Knight
Simon J. Fisher
Owen Chan
Publikationsdatum: 09.01.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Diabetologia / Ausgabe 4/2019
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-018-4802-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Carvedilol prevents counterregulatory failure and impaired hypoglycaemia awareness in non-diabetic recurrently hypoglycaemic rats

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis

Correction to: Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C

Inappropriate glucagon and GLP-1 secretion in individuals with long-standing type 1 diabetes: effects of residual C-peptide

Effect of Roux-en-Y gastric bypass surgery on diabetes remission and complications in individuals with type 2 diabetes: a Danish population-based matched cohort study

The discovery of novel predictive biomarkers and early-stage pathophysiology for the transition from gestational diabetes to type 2 diabetes

Empagliflozin enhances human and murine cardiomyocyte glucose uptake by increased expression of GLUT1

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin